Literature DB >> 10867535

Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis.

C Y Tsai1, T H Wu, C L Yu, J Y Lu, Y Y Tsai.   

Abstract

Tubulointerstitial nephritis is a less frequently recognized but important complication of systemic lupus erythematosus. We have investigated the cytokine beta2-microglobulin (beta2M) and Tamm-Horsfall glycoprotein (THG) excretions in the urine of systemic lupus erythematosus patients to identify indices for evaluation of tubulointerstitial inflammation in lupus nephritis (LN). Daily urine was collected from 15 patients with active LN, from 12 patients with inactive LN, and from 17 normal subjects. The amounts of soluble interleukin (IL) 2 receptor, IL-6, IL-8, beta2M, and THG in urine were measured. Beta2M and THG were regarded as indicators of proximal and distal renal tubule function, respectively. The urinary excretions of IL-6 and IL-8 were significantly higher in patients with active LN than in those with inactive LN and in normal individuals. The excretion of soluble IL-2 receptor in all three groups of subjects was not significantly different. On the other hand, the excretion of beta2M in patients with LN was significantly higher than that in normal individuals. The excretion of beta2M in patients with active or inactive LN was not significantly different. The THG excretion was lower in patients with active LN and tubulointerstitial inflammation as compared with patients with inactive LN or normal individuals. Six patients underwent pulse cyclophosphamide therapy during the course of experiments. Five of them showed a decrease in IL-8 and IL-6 excretions in urine after the treatment. The excretions of beta2M and THG in urine, in addition to IL-6 and IL-8, can reflect the renal inflammatory activity in patients with lupus tubulointerstitial nephritis as well as in those having lupus glomerulonephritis. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867535     DOI: 10.1159/000045663

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  55 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

Review 3.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

4.  Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein.

Authors:  Yan Liu; Lan Mo; David S Goldfarb; Andrew P Evan; Fengxia Liang; Saeed R Khan; John C Lieske; Xue-Ru Wu
Journal:  Am J Physiol Renal Physiol       Date:  2010-06-30

Review 5.  [Biologics therapy for systemic lupus erythematosus. Current situation].

Authors:  B F Hoyer; T Dörner
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

Review 6.  Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 7.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

8.  Successful relatively low-dose corticosteroid therapy for diclofenac-induced acute interstitial nephritis with severe renal failure.

Authors:  Makoto Inoue; Tetsu Akimoto; Osamu Saito; Yasuhiro Ando; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2008-02-15       Impact factor: 2.801

9.  Selectively reduced expression of thick ascending limb Tamm-Horsfall protein in hypothyroid kidneys.

Authors:  Roland Schmitt; Thomas Kahl; Kerim Mutig; Sebastian Bachmann
Journal:  Histochem Cell Biol       Date:  2004-03-09       Impact factor: 4.304

Review 10.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.